Furthermore, we have demonstrated a correlation of neutropenia, an adverse event from CDK 4/6 inhibitor therapy, as a possible biomarker of clinical benefit from CDK4/6 inhibitor therapy. The gene discussed is CDK4; the disease is neutropenia.